INDEX TO VOLUME 87

Aalbers, R., B1, B3–7, B13–21, B23–24, B57–60
Abbott, J., 9–15
Adam, K. A. R., 69–72
Adenoidal bacteriology, 303–308
Adenosine 3′ 5′ cyclic monophosphate, 445–448
Aging lung; epidemiology, 5–7
β-Agonists
  increasing doses, in chronic airflow limitation, 433–438
Ahmed, T., 235
AIDS, pneumothorax, 43–47, 400
Ainslie, G., 169–174
Airway epithelial cells and inflammation, 406–408
Airway mucins, 421–426
Airway obstruction, mean transit time evaluation, 319
Airways, effect of salbutamol, 23–27
Akkoclu, A., 397
Akpinar, O., 397
Alexander, M., 609–620
Ali, J. M., 235
Alkali nebulization and bronchostriction, 235
Al Jarad, N., 309–312, 365–374
Allen, M. B., 99–103
Allergic alveolitis; new insights, 495–501
Allergic bronchopulmonary aspergillosis, 237–238
Almitrine bismesylate, 93–98
Alveolar volume, 115–120
Alveolitis, allergic; new insights, 495–501
Alveolitis, fibrosing, 313–314
Al-Sharif, A. F., 235
Anderson, M. L. M., 413–420
Andrews, J. M., 595–601
Andrews, S., 225–226
Androgens in bronchial carcinoma, 455–460
Antibiotics
  and acute exacerbations of bronchiectasis, 449–454
  intravenous, in cystic fibrosis, 329–330
  prescribing for cystic fibrosis, 535–539
Anti-neutrophil cytoplasmic antibodies, 240
Arshad, H., 299–302
Arteriolar pulmonary resistance, 158
Asbestos-related pericardial thickening detected by MRI, 309–312
Asbestos workers, prognostic factors, 365–374
Asbestosis
  advanced, 115–120
  measuring lung volumes, 115–120
Ashour, M., 69–72, 400
Assoufi, B. K., 587–593
Asthma
  acute, bronchial, 235
  acute, severe, 29–35
  alkali nebulization, 235
  allergic, B3–7
  bambuterol, 581–585
  beclomethasone dipropionate, 609–620
  bronchial, B13–21
  bronchial biopsies, B23–24
  bronchial epithelial shedding, B9–11
  bronchial hyperresponsiveness, 29–35, 133–138, 165–167, B3–7
  bronchoconstriction, exercise-induced, 439–444
  coping with, B67–70
  corticosteroids, 261–277, A23–26
  early response, 121–126
  exercise-induced, 331–344
  fenoterol, 636–638
  fluticasone propionate, 609–620
  hypothalamo-pituitary-adrenal axis suppression, 321
  immunohistology, B13–21
  and infection, 165–167
  labelling shift from acute bronchitis, 183–186
  leukotriene antagonist ONO-1078, 133–138
  methacholine, 23–27
  methotrexate, B57–60
  mild, 23–27, 439–444
  mortality, 183–186
  nedocromil sodium, 517–523
  nocturnal, 581–585, B37–39
  occupational compensation, 569–570
  and osteoporosis, A9–14
  patients aged over 50 years, 517–523
  pulmonary rehabilitation, B41–44
  respiratory arrests and salmeterol, 227–228, 638–639
  salbutamol, 23–27, 121–126, 636–638
  salmeterol, 227–228, 439–444, 638–639
  severe, 29–35, 139–143, B57–60
  and social class, 139–143
  sodium cromoglycate, 299–302, 517–523
  stable, 439–444
  treatment development, B53–56
  see also Childhood asthma; Chronic asthma
Atkinson, B., 551–553
Aydilek, R., 635
Ayres, J. G., 183–186, 509–516, 517–523

Bacci, E., 121–126
Bacteriology of tonsil and adenoid, 303–308
Baigrie, R. J., 285–288
Baldwin, D. R., 223–224, 595–601
Balfour, T., 223–224
Balkanli, K., 635
Ball, A. B. S., 147–148
Bambuterol in nocturnal asthma, 581–585
Bancalari, L., 121–126
Barnes, N. C., 237, A20, A21, A26, A27–31, A35, A36, B53–56
Bar-Yishay, E., 331–334
Bateman, E. D., 485–487
Beasley, R., 637
Beclomethasone dipropionate, 609–620
  in children, 445–448
Beech, C., 491–494
Benatar, S. R., 158
Berkman, N., 85–92, 571–579
Beveridge, C. J., 629
Bhatnagar, N. K., 489–490
Bilateral hilar enlargement with parenchymal homogeneous density, 635
Black, D., 375–378
Blair, I., 509–516
Blood gas techniques, 79–80
Boldy, D. A. R., 517–523
Bone marrow transplantation, pulmonary complications, 571–579
Bone metabolism and corticosteroids, A33–36
Bone physiology, A3–7
Bone turnover
  and corticosteroids, A15–21
  measurement methods, A9–14
  Workshop Review, A1–37
Bourke, S. J., 61–63
Bouros, D., 351–358
Bowman, A., 455–460
Boyd, G., A1, A20, A35, A36, A37
Brear, S. G., 320
Breathing, nasal, preferential, in adults, 295–297
Bremmer, P., 637
Breuer, R., 85–92, 571–579
Bron, A. O., B37–39
Bronchial biopsies in asthma, B23–24
Bronchial carcinoma, 149–151, 455–460
Bronchial epithelial shedding, B9–11
Bronchial hyperresponsiveness, 133–138
  allergic asthma, B3–7
  acute severe asthma, 29–35
  in COPD, B3–7

direct and indirect, B31–36
and infection, 165–167
today, B27–29
Bronchial rupture, fibrin glue repair, 397
Bronchiectasis
acute exacerbations of, 449–54
and antibiotics, 449–454
spirometric variables, 395–396
Bronchoalveolar concentrations of ciprofloxacin and lomefloxacin following oral administration, 595–601
Bronchoalveolar lavage
in asbestos workers, 365–374
practical aspects, B25–26
Bronchoconstriction
and alkali nebulization, 235
fog-induced, 65–67
in preterm infants, 37–42
and salmeterol, 439–444
sodium cromoglycate protection, 37–42
Bronchodilator therapy, response in young children born prematurely, 359–364
Bronchodilator response to nebulized salbutamol in elderly patients, 375–378
Bronchoscopy, fibre optic, 105–109
Brown, P., 321
Brunet, F., 565–568
Burge, P. S., 105–109, 509–516
Burgess, C., 637
Butler, J., 285–288

Cafferkey, M. T., 303–308
Calderon, J., 158
Callol, L., 158
Campbell, I. A., 621–623
Cancer
bronchial carcinoma, 455–460
intrathoracic tumours in children, 467–469
malignant mesothelioma of pleura, 147–148
pulmonary involvement in lymphoma, 85–92
Capron, F., 229–230
Capsaicin, cough induced by, in healthy volunteers, 379–382
Carbon monoxide and exercise performance, 427–431
Carcinoma, bronchial, 149–151
Cardiopulmonary bypass
inflammation and pentoxifylline, 285–288
respiratory dysfunction following, 193–198, 557–558
Carpenter, M. J., 509–516
Carrara, M., 121–126
Carroll, M. P., 387–394
Carswell, J. W., 398
Carter, R., 193–198, 557
Cats, cough sounds, 49–54, 55–59
Catterall, J. R., 1–3
Caubarrere, I., 559
Caul, E. O., 509–516
Cayton, R. M., 541–549
CD_4 cell count, 153–155
Celik, M., 635
Chan, C. H. S., 383–385
Chemotherapy for lymph node tuberculosis, 621–623
Childhood asthma
fog-induced bronchoconstriction, 65–67
ipratropium bromide, 111–114
nedocromil sodium, 65–67
terbutaline, 111–114
Children
born prematurely, bronchodilator therapy, 359–364
chronic asthma and BDP, 445–448
intrathoracic tumours in, 467–469
sodium cromoglycate, 299–302
spontaneous pneumothorax in, 531–534
Wright flow meter evaluation, 551–553
Chillon, M. J., 158
Cholecystectomy, laparoscopic, in patients with cystic fibrosis, 223–224
Chong, J. L., 285–288
Chookang, J. Y., 581–585
Choudry, N. B., 29–35
Chronic airflow limitation, effect of β-agonists, 433–438
Chronic airflow limitation, stable, in elderly patients, 375–378
Chronic asthma
and beclomethasone dipropionate, 445–448
in children, 445–448
CsA, 319
methotrexate 30 mg per week, 211–216
nedocromil sodium, 238–239
steroid-dependent, 211–216
Chronic obstructive pulmonary disease (COPD)
bronchial hyperresponsiveness, B3–7
inflammation, B3–7
and lung transplantation, B61–65
nasal ventilation, 387–394
nutritional depletion, B45–47
pulmonary rehabilitation, B41–44
respiratory muscle function, B49–51
treatment development, B53–56
Chronic respiratory disease, nasal ventilation, 199–204
Cimrin, A., 397
Ciprofloxacin
in adult cystic fibrosis, 587–593
bronchoalveolar concentration, 595–601
Clark, C. E., 227–228
Clark, F., 149–151
Clarke, K. W., 320
Clauvel, J. P., 559
Claydon, E., 43–47
Clear-cell carcinoma of the lung, 471–473
Coker, R. J., 43–47
Collins, J. V., 525–529
Compensating occupational asthma, 569–570
Computer system for a respiratory medicine department, 491–494
Conway, J. H., 387–394
Cook, D., 433–438
Cordon, S. M., 603–607
Cornwell, W. E., 199–204
Coronary artery bypass surgery, 157
Corris, P. A., 61–63
Corticosteroids
in asthma, 261–277, A23–26
effects on bone turnover (Workshop Review), A1–37
and growth, A23–26
safety of, A27–31
and tuberculosis chemoprophylaxis, 485–487
Cortisol, 445–448
Couderc, L. J., 559
Cough
capsaicin-induced, in healthy volunteers, 379–382
chronic, management, 249–251
and lung oedema, 55–59
and simulated mucus, 49–54
sounds, in cats, 49–54, 55–59
Coupland, B., 509–516
Crane, J., 637
Crompton, G. K., 321
CsA, 319
Cushing's syndrome, 149–151
Cystic fibrosis
adult, 9–15
antibiotic prescribing practices, 535–539
endurance exercise capacity in adults, 541–549
exercise training, B49–51
intravenous antibiotics, 329–330
and laparoscopic cholecystectomy, 223–224
nutrition, B49–51
oral ciprofloxacin, 587–593
pre-death host inflammatory response, 603–607
Pseudomonas aeruginosa infection, 587–593

and *Pseudomonas cepacia* infection, 187–192
S. newport in sputum, 625–627
spirometric variables, 395–396
Cytokines and the lung. Abstracts of 12th summer meeting of the British Association for Lung Research, 641–656
Cytomegalovirus pneumonia, 345–349

D'Agay, M. F., 229–230
Davidson, A. C., 237
Davidson, K. G., 455–460
Davies, M. J., 145–146
Davies, R. J., 23–27, 165–167, 211–216, 405–408
Davies, R. J. O., 503–507
Davis, A. M., 531–534
Davison, J. R., 551–553
Day, J., 609–620
de Boer, W. J., B61–65
Deenen, Th. A. M., B67–70
Delamere, F. M., 603–607
de Monchy, J. G. R., B23–24
Dente, F. L., 121–126
Desselberger, U., 509–516
Devalia, J. L., 405–408
Devlin, B., 61–63
Dhainaut, J. F., 565–568
Dhillon, D. P., 439–444
Di Franco, A., 121–126
Diffuse panbronchiolitis; efficacy of erythromycin, 229–230
Dilworth, P., 236
Dinsdale, D., 279–284
DNA amplification by PCR, 525–529
Dodd, M., 9–15

Earnshaw, J., 439–444
Eastell, R., A13, A14, A20, A26
Eccles, R., 379–382
Ectopic ACTH secretion, 149–161
Edwards, A., 149–151
Edwards, A. M., 239
Elborn, J. S., 603–607
Elderly patients with stable chronic airflow limitation; response to salbutamol, 375–378
El-Din Hawass, N., 69–72
El-Fiky, M. M., 193–198
Emphysematous disease, single lung transplantation for, 489–490
Endocrinopathies, respiratory muscles in, 351–358
Eosinophilia, tropical, 17–21
Epidemiology: the aging lung, 5–7
Epidemiology of nocturnal asthma, B37–39
Epithelium, respiratory tract, and neoplasia, 175–181
Erythromycin in diffuse panbronchiolitis, 229–230
Evans, A., 445–448
Evans, M., 509–516
Everett, L., 111–114
Evrenoglou, D., 93–98
Exercise endurance capacity in adults with cystic fibrosis, 541–549
Exercise-induced asthma, 331–344
Exercise performance, effect of carbon monoxide, 427–431
Exercise performance, effect of nicotine, 427–431
Exercise training in cystic fibrosis, B49–51
Extracorporeal circulation for respiratory support in adults, 565–568

Faichney, A., 455–460
Family clusters of pulmonary tuberculosis in Japan, 205–209
Farrell, I. D., 509–516
Feneck, R. O., 199–204
Fenoterol, 636–638
Ferguson, A. D., 227–228
Ferguson, H., 23–27
Fibre optic bronchoscopy value audit in pneumonia, 105–109
Fibrin glue repair of bronchial rupture, 397
Fibrosing alveolitis, 313–314
Fitzgerald, M. J., 433–438
Flow meter evaluation in children and adults, 551–553
Fluticasone propionate, pressurized or dry powder, 609–620
Fog-induced bronchoconstriction, 65–67
Folgering, H., B41–44
Foster, C., 375–378
Frankland, A. W., 551–553
Freeman, D. F., 303–308
Freeman, W., 541–549
Fretts, C., 5–7
Friend, J. A. R., 621–623
Frija, J., 229–230
Fujimura, M., 133–138

Gaffney, R. J., 303–308
Gamsu, H. R., 217–221
Gas exchange in liver cirrhosis, 93–98
Gaya, H., 187–192
Gazzard, B. G., 525–529
Gellert, A. R., 365–374
Geraghty, R., 375–378
Gerber, F., 229–230
Giannini, D., 121–126
Gibson, G. J., 61–63, 149–151
Gibson, S. P., 105–109
Gill, M., 595–601
Giuntini, C., 121–126
Glaucoma and nebulized bronchodilator therapy, 559–561
Gleeson, M. J., 225–226
Godfrey, R. C., 387–394
Godfrey, S., 331–344
Goldstraw, P., 399
Gomez-Terreros, F. J., 158
Gonadotrophins in bronchial carcinoma, 455–460
Goodwin, A., 299–302
Grange, J. M., 398
Granuloma, plasma cell, 555–556
Gray, C. E., 455–460
Greening, A. P., 321
Greenough, A., 37–42, 111–114, 217–221, 359–364
Growth and corticosteroids, A23–26
Growth hormone, 445–448
Guyatt, G. H., 433–438

Haas, J. F., 636
Haddon, R., 433–438
Haemodynamics in liver cirrhosis, 93–98
Hall, D. R., 145–146
Hamilton, P., 400
Hamilton-Wood, C., 471–473
Hammond, J. M. J., 325–328
Hara, N., 475–477
Hardy, J. G., 461–465
Harper, S., 433–438
Harris, J. R. W., 43–47
Hassan, W. U., 240, 581–585
Hawker, J. I., 509–516
Hayhurst, M. D., 161–163
Herbert, J., 609–620
Heijerman, H. G. M., B49–51
Helium rebreathing, 115–120
Hematuria after respiratory tract infection, 73–74
Henderson, A. F., 240
Herdman, M. J., 23–27
Herwaarden, C.v., B41–44
Hide, D., 299–302
Hirano, H., 475–477
Hirsch, A., 229–230
Hitchcock, R. A., 387–394
HIV
and lung limited lymphocytic proliferation, 559
and *Pneumocystis carinii*, 525–529
Ho, J., 382–385
Hodson, M. E., 187–192, 535–539, 587–593
Holgate, S. T., B9–11
Holzer, R., 609–620

Honeybourne, D., 595–601
Hosking, D. J., A13, A14, A15–21, A35, A36
Host inflammatory response, pre-death, in patients with cystic fibrosis and chronic *P. aeruginosa* infection, 603–607
Hotta, I., 205–209
Hough, A., 157
Howes, T., 236
Hudson, M., 320
Hughes. I., A35
Hughes, J., A31
Hutchings, H. A., 379–382
Hydatic cysts, 635
Hypercapnic respiratory failure, 409–411
Hypothalamo-pituitary-adrenal axis suppression, 321

Immunohistology in bronchial asthma, B13–21
Ind, P. W., 29–35, A14, A31
Infants, preterm
  bronchoconstriction, 37–42
  sodium cromoglycate, 37–42
Inflammation
  cardiopulmonary bypass, and pentoxifylline, 285–288
  mediators of, 405–408
Ingram, C. G., 439–444
Inhalational injuries caused by smoke and nitrogen dioxide, 169–174
Interleukin-2 receptors and lung cancer surgery, 383–385
Intestinal obstruction, 147–148
Intrapleural rupture of mediastinal teratoma, 69–72, 399
Intrathoracic tumours in children, 467–469
Ip, M., 449–454
Ipratropium bromide in asthmatic children, 111–114
Iredale, M., 236
Israel, H. L., 81–83, 153–155

Jaeschke, R., 433–438
Jansen, H. M., B25–26
Jawad, M. S. M., 379–382
Jeffries, D. J., 525–529
Jenkins, P. A., 621–623
Joharjy, I., 69–72
John, P. J., 395–396
Jones, A., 299–302
Jones, A. L., 609–620
Joos, G. F., B31–36

Kamio, Y., 133–138
Kane, G. C., 153–155
Kangro, H. O., 525–529
Karlikaya, C., 397
Kauffmann, F., 5–7
Keogh, B. F., 245–247
Kesten, S., 609–620
Kilburn, K. H., 115–120
Kinnear, G., 65–67
Kips, J. C., B31–36
Klip, E. C., B67–70
Knoch, M., 461–465
Knox, A., 329–330
Knox, A. J., 223–224
Kondo, T., 205–209
Korpáš, J., 49–54, 55–59
Kudlička, J., 55–59
Kuipers, E. J., 73–74
Kunter, E., 635

Lai, C. K. W., 383–385
Lai, K. N., 383–385
Lam, W. K., 449–454
Lamblin, G., 421–426
Lampropoulos, S., 93–98
Langford, S. A., 99–103
Lauder, I., 449–454
Leigh, T. R., 525–529
Leitch, A. G., 321, 629

Leukotriene antagonist, ONO-1078, 133–138
Leung, J. C. K., 383–385
Littlejohns, P., 139–143
Liver cirrhosis, 93–98
Lomefloxacin bronchoalveolar concentration, 595–601
Lossos, I. S., 571–579
Lundback, B., 609–620
Lung cancer
  bronchial carcinoma, 149–151
  clear-cell carcinoma, 471–473
  communicating the diagnosis, 61–63
  Cushing's syndrome, 149–151
  interleukin-2 receptors in, 383–385
  oncogenes and onco-suppressor genes, 413–420
  respiratory tract epithelium and neoplasia, 175–181
  surgery, 383–385
  in young patients of South India, 399
Lung deposition from four nebulizers, 461–465
Lung limited lymphocytic proliferation in HIV, 559
Lung oedema and cough sound creation, 55–59
Lung rest, 245–247
Lung and sleep, 503–507
Lung toxicology, 279–284
Lung transplantation and COPD, B61–65
Lung transplantation, single, for emphysematous disease, 489–490
Lung tumour, pulmonary sclerosing haemangioma, 475–477
Luyt, D., 299–302
Lymph node tuberculosis, chemotherapy, 621–623
Lymphoma, pulmonary involvement, 85–92

McCarty, M., 43–47
Macdonald, L. D., 139–143
Macfarlane, J. T., 289–294
McGlashan, J. A., 225–226
McHardy, G. J. R., 629
McIlroy, W., 433–438
McNamee, C. J., 471–473
McNicol, M. W., 427–431
Maddison, J., 9–15
Magnetic resonance imaging detection of asbestos-related pericardial thickening, 309–312
Mahashur, A. A., 395–396
Malo, J. L., 569–570
Mannes, G. P. M., B61–65
Matsuda, T., 133–138
Maule, B. H., 193–198
Maxwell, D. L., 225–226
Mean transit time, 319
Mediastinal emphysema, 313–314
Mediastinal teratoma, 69–72, 399
Mediastinal teratoma rupture, 69–72
Meecham-Jones, J., 236
Meijer, G. G., B37–39
Mesothelioma, malignant, of the pleura, 147–148
Methacholine, 23–27
Methotrexate, 153–155, 211–216, B57–60
Meuzelaar, J. J., B61–65
Meyns, B., 471–473
Micro-organisms, defence against, 421–426
Miller, A., 115–120
Miller, M. R., 319
Millhollon, B. W., 495–501
Milner, A. D., 65–67
Mitchell, D., 43–47
Miyagawa, Y., 475–477
Miyao, M., 205–209
Montefort, S., B9–11
Morgan, J. R., 320
Morgan, M. D. L., 541–549
Morris, D. J., 345–349
Morris, J., 433–438
Morris, R. W., 551–553
Morris, S., 379–382
Morrison, J. F., 581–585

Moss, F., 43–47
Mucins, airway, 421–426
Mucus, simulated, 49–54
Munro, N. C., 61–63, 400, 638
Murray, M., 65–67
Muscle function, B49–51
Muscles, respiratory, in endocrinopathies, 351–358

Nagata, N., 475–477
Nakanishi, Y., 475–477
Nakos, G., 93–98
Nasal breathing, preferential, in adults, 295–297
Nasal ventilation in chronic obstructive pulmonary disease, 387–394
Nasal ventilation and chronic respiratory disease; weaning from assisted ventilation, 199–204
Nebulized bronchodilator therapy causes acute closure glaucoma, 559–561
Nebulized sodium cromoglycate, 37–42
Nebulizers, jet, salbutamol output from, 99–103
Nebulizer lung deposition, 461–465
Nebulizer treatment, home, 157
Nedocromil sodium
  in asthma patients aged over 50 years, 517–523
  in asthmatic children, 65–67
  in chronic asthma, 238–239
Neonatal surfactant replacement therapy, 217–221
Neurilemoma, 145–146
Neurofibroma, 145–146
Newman, S. P., 465
Newnham, D. M., 439–444
Newhouse, M., 433–438
Nicholls, D. P., 295–297
Nicotine and exercise performance, 427–431
Nieman, R., 43–47
Nikolaizik, W. H., 467–469
Ninan, T. K., 320
Ning, C. W. S., 581–585
Nitrogen dioxide, inhalational injuries, 169–174
Nocturnal asthma
  epidemiology, B37–39
  underlying mechanisms, B37–39
Nocturnal respiratory research, 503–507
Nutrition in cystic fibrosis, B49–51
Nutritional depletion in COPD, B45–47

O'Brien, C., 559–561
O'Connor, I., 313–314
O'Driscoll, B. R., 157
Ohta, M., 475–477
Oncogenes in lung cancer, 413–420
Onco-suppressor genes in lung cancer, 413–420
ONO-1078, 133–138
Oosterhoff, Y., B37–39
Or, R., 571–579
Oreffo, V. I. C., 175–181
O'Reilly, J. F., 581–585
Ormerod, L. P., 127–131, 621–623
Osteoporosis
  and asthma, A9–14
  clinical evaluation of, A9–14
  and corticosteroids, A9–14
Osteoporotic process, A3–7
Oto, O., 397
Oxygen therapy, domiciliary, hazards of, 225–226

Paggiaro, P. L., 121–126
Pagliero, K. M., 471–473
Palmer, J. B. D., 439–444
Pantin, C. F. A., 491–494
Parker, D., 285–288, 603–607
Patel, B., 239
Pauwels, R. A., B31–36
Pearce, N., 637
Pearson, S. B., 581–585
Peckham, D., 329–330
Pentoxifylline, cardiopulmonary bypass inflammation, 285–288
Pericardial thickening, asbestos-related; MRI detection, 309–312
Peters, B., 43–47
Peters, S. P., 153–155
Petrie, G. R., 581–585
Phelan, P. D., 531–534
Pillai, R., 285–288
Plasma cell granuloma, 555–556
Plethysmography, 115–120
Pleural effusions, 236–237
Pleural malignant mesothelioma, 147–148
Pneumocystis carinii and HIV, 525–529
Pneumomediastinum, 313–314
Pneumonia
  audit of fibre optic bronchoscopy, 105–109
  CD_4 cell count, 153–155
  community acquired, 105–109, 289–294
  cytomegalovirus, 345–349
  methotrexate, 153–155
  Pneumocystis carinii, 153–155
Pneumothorax in AIDS patients, 43–47, 400
Pneumothorax, spontaneous, in paediatric patients, 531–534
Postmus, P. E., 73–74
Potgieter, P. D., 325–328
Pozniak, A., 398
Prescott, R. J., 621–623
Prescribed respiratory diseases in the 1990s, 79
Price, J. F., 111–114, A13, A14, A23–26
Prior, A. J., 147–148
Pseudomonas aeruginosa infection in cystic fibrosis patients, 587–593
Pseudomonas aeruginosa infection, pre-death host inflammatory response, 603–607
Pseudomonas cepacia pulmonary infection in cystic fibrosis patients, 187–192
Pulmonary complications of bone marrow transplantation, 571–579
Pulmonary function testing, preoperative, 161–163
Pulmonary involvement in lymphoma, 85–92
Pulmonary rehabilitation in asthma and COPD, B41–44
Pulmonary sclerosing haemangioma diagnosis, 475–477
Pulmonary tuberculosis in Japan, 205–209

Q fever outbreak; clinical aspects, 509–516

Radford, M., 445–448
Radiographic lung area, 115–120
Raine, R. I., 253–259
Ramsdale, H., 433–438
Reid, D. M., A9–14, A21, A26, A35, A36
Respiratory arrests in young asthmatics on salmeterol, 227–228, 638–639
Respiratory dysfunction following cardiopulmonary bypass, 193–198, 557–558
Respiratory failure, hypercapnic, 409–411
Respiratory medicine department computer system, 491–494
Respiratory tract epithelium and neoplasia, 175–181
Respiratory tract infection, macroscopic hematuria after, 73–74
Restrick, L. J., 199–204, 236
Richards, R. J., 175–181
Rider, M. A., 555–556
Rifampicin in steroid-dependent asthma, 629
Roche, W. R., B9–11
Rocker, G. M., 285–288
Roe, S., 375–378
Rook, G. A. W., 398
Ross, B. A., 145–146
Roussel, P., 421–426
Roussos, C., 409–411
Rudd, R. M., 309–312, 365–374
Rupture, intrapleural, of mediastinal teratoma, 69–72
Russel, G., 320

Sahoo, R. C., 399
Sakakibara, H., 205–209
Sakamoto, S., 133–138
Salbutamol, 636–638
  controlled release; airway responsiveness, 23–27
  in elderly patients with stable chronic airflow limitation, 375–378
  mild asthma, 23–27
  output from two jet nebulizers, 99–103
Salmeterol
  and bronchoconstriction, 439–444
  and respiratory arrests in young asthmatics, 227–228, 638–639
Salmonella newport in cystic fibrosis, 625–627
Salvaggio, J. E., 495–501
Sanderson, M., 236
Saunders, K. B., 557
Schols, A. M. W. J., B45–47
Scott, A. D., 199–204
Scott, D., 400
Seaton, A., 237
Selective decontamination, 325–328
Sell, L., 61–63
Senior registrar appointments freeze, 236
Shale, D. J., 285–288, 603–607
Shaw, R. J., 261–277
Sheldon, C. D., 237, 587–593
Shneerson, J. M., 581–585
Shum, D., 449–454
Shunt fraction measurement, 193–198, 557–558
Siafakas, N. M., 351–358
Siddorn, J. A., 227–228
Sim, K. M., 245–247
Simpson, R. H. W., 471–473
Singh, J., 559–561
Sleep apnoea and snoring, 1–3
Sleep and the lung, 503–507
Sleep-related breathing disorders, 253–259
Smith, D. L., 509–516, 625–627
Smith, E. G., 509–516–625–627
Smith, M., B13–21
Smith, R., A3–7, A14, A26, A31, A36
Smoke inhalational injuries, 169–174
Smoking, 157
Snead, D., 555–556
Snoring and sleep apnoea, 1–3
So, S. Y., 449–454
Social class and severe asthma, 139–143
Sodium cromoglycate
  in asthma patients aged over 50 years, 517–523
  in preterm infants, 37–42
  via inhaler and autohaler, 299–302
Soutar, C., 629
Spandidos, D. A., 413–420
Spontaneous pneumomediastinum in patient with fibrosing alveolitis, 313–314
Sputum, inflammatory contents; effect of antibiotics, 449–454
Sputum of patient with cystic fibrosis, *S. newport* in, 625–627
Sridhar, G., 629
Stableforth, D. E., 541–549, 625–627
Stanford, C. A., 398
Stanford, C. F., 295–297
Stanford, J. L., 398
Staudinger, H. W., 636
Sterk, P. J., B27–29
Steroid-dependent asthma, 211–216, 629
Stockwell, M. C., 193–198
Stone, R., 249–251
Sullivan, R., 319
Surfactant replacement therapy, neonatal, 217–221
Surgery, lung cancer, 383–385

Taggart, D. P., 193–198, 455–460
Tang, C. M., 289–294
Tang, O. T., 581–585
Taskar, V. S., 395–396
Taylor, I. K., 261–277
Taylor, R. F. H., 187–192, 535–539
^{99m}Tc-DTPA clearance in asbestos workers, 365–374
Teratoma, mediastinal, 69–72, 399
Terbutaline in asthmatic children, 111–114
Testi, R., 121–126
Thomas, G. O., 313–314
Thomas, K., 23–27
Thoracoscopy, 236–237
Timens, W., B13–21, B23–24
Timon, C. I., 303–308
Tong, P., 149–151
Tonsil bacteriology, 303–308
Toxicology of the lung, 279–284
Tracheal tumours, rare, 145–146
Transbronchial needle aspiration, 475–477
Tredaniel, J., 229–230
Trigg, C. J., 23–27, 165–167, 211–216
Tropical eosinophilia, a review, 17–21
Troshinsky, M. B., 153–155
Tuberculosis
  a century of, 158
  chemoprophylaxis, 81–83, 398, 485–487
  contact tracing (Blackburn 1982–90), 127–131
  lymph node, 621–623
  pulmonary; family clusters, 205–209
Tumours
  intrathoracic, in children, 467–469
  tracheal, rare, 145–146
Turbitt, M. L., 581–585
Turner, G., 400
Turner, J. A. McM., 427–431

Ucan, E., 397, 635
Udwadia, F. E., 17–21
Udwadia, Z. F., 629
Underwood, S. R., 309–312

Vagaggini, B., 121–126
van Aalderen, W. M. C., B37–39
van den Bosch, J. M. M., B25–26
van der Bij, W., B61–65
Van Uffelen, R., 609–620
Vassilakis, N., 93–98
Ventilation, nasal
  in chronic obstructive pulmonary disease, 387–394
  in chronic respiratory disease, 199–204
Villegas, F. R., 158
Vrabec, M., 49–54, 55–59
Vrugt, B., B3–7

Walker, C., B57–60
Walsh, M. A., 303–308
Ward, A. K., 295–297
Ward, E. M., 199–204
Ward, M. J., A33–36
Warner, J. O., 467–469
Warshaw, R. H., 115–120
Webb, A. K., 9–15
Wedzicha, J. A., 199–204
Weir, D. C., 105–109
Wells, A., 239
Wensley, D. F., 531–534
Westaby, S., 285–288
Whallett, E. J., 183–186
Wheatley, D. J., 193–198, 557
White, A., 149–151
White, J., 149–151
Whyte, M. K. B., 29–35
Widdicombe, J. G., 49–54, 55–59
Wikeley, N. J., 239
Willan, A., 433–438
Williams, I., 299–302

Winney, J. D. J., 103
Winocour, P. H., 149–151
Wise, R., 595–601
Wood, A., 400
Wood, M. J., 509–516
Wood, P., 445–448
Wostenholme, R. J., 157
Wouters, E. F. M., B45–47
Wright, M., 559–561
Wright flow meter evaluation in children and adults, 551–553

Yagawa, K., 475–477
Yalcin, Z., 635
Yamada, S., 205–209
Yamanaka, K., 205–209
Yntema, J. L., B57–60
Yuksel, B., 37–42, 111–114, 217–221, 359–364

Zakynthinos, S., 409–411
Zalcman, G., 229–230
Zeitlin, S., 445–448